The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1483
Deoxycholic Acid (Kybella) for Double Chin
The full article is available to subscribers Subscriber Login   

The FDA has approved the use of subcutaneous injections of deoxycholic acid (Kybella – Kythera/Allergan) to improve the appearance of moderate to severe convexity or fullness associated with submental fat (double chin) in adults. It is the first drug approved for this indication.

MECHANISM OF ACTION — Deoxycholic acid is an endogenous bile acid that solubilizes dietary fat in the gut.1 Kybella contains synthetically derived deoxycholic acid. When the drug is injected into subcutaneous fat tissue, it solubilizes lipids in adipocyte membranes. The resulting cytolysis induces an inflammatory response that clears cell debris.2

CLINICAL STUDIES — Approval of deoxycholic acid was based on the results of two unpublished, randomized, placebo-controlled trials (REFINE-1 and REFINE-2), which ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Deoxycholic Acid (Kybella) for Double Chin
Article code: 1483c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian